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ABSTRACT  
Background: Patients with β-thalassemia major (TM) develop iron overload through increased iron 
absorption and transfusional therapy and it’s the most important complication of TM. Thalassemia is common 
in coastal regions and lands with low altitudes. The aim of this study is to determine the effect of high and low 
altitude on serum ferritin and treatment requirement in two groups of β-thalassemia major (TM) patients. 
Subjects and Methods: Patients were divided into two groups, the first group (No: 50) living at sea level (in 
the port of Bushehr, Iran) and the second group (No: 40) living at the altitude of 2061 m (in the city of 
Shahrekord, Iran). All patient’s clinical history, blood transfusion and laboratory tests including complete blood 
count and hemoglobin electrophoresis were reviewed. 
Results: There were no significant difference in ferritin levels, transfusion period and diabetes incidence of 
the two cities patients (P>0.05). Patient’s cardiac function and liver condition were significantly better in 
patients of Bushehr (P<0.05). Patients under 20 years in Bushehr were less splenectomized in comparison 
with Shahrekord (P<0.05). 
Conclusion: Our result showed that some of clinical manifestations of patients in low altitude such as cardiac 
and liver condition were better. But it did not affect ferritin level probably due to transfusion and chelating 
therapy. Totally patients of Bushehr had better conditions and had longer survivals. 
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INTRODUCTION 
   β-thalassemia major is an inherited form of 
hemolytic anemia , characterized by abnormal 
production of red blood cells. It is a worldwide 
hereditary blood disorder, highly prevalent in 
Mediterranean countries, Middle East, Central Asia, 
India, Southern China and the Far East as well as 
countries along the north coast of Africa and South 
America.1,2 It has been estimated that % 1.5 of 
world population are carriers of β-Thalassemia.3 
The manifestations of the disease include 
myocarditis and iron overload which seem to be 
involved in the pathogenesis of left and right 
ventricular dysfunction and enlargement, 
respectively. Also, the mechanical efficiency of the 
heart in TM patients has been reported to decrease 
by arterial stiffness, endothelial dysfunction and LV 
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hypertrophies.4 The manifestations of the disease 
are reported to be aggravated by hypoxemia. 
Erythropoietin in the blood circulation is sensitive to 
arterial blood O2 pressure and increases under 
hypoxic conditions.5 Therefore, at high altitudes 
where the oxygen pressure is reduced, the 
erythropoietin level in the blood rises and the total 
erythrocyte mass would increase which results in 
the early destruction of spleen and increase in the 
risk of splenectomy. 
Transfusion therapy may increase iron absorption 
and results in iron overload in patients with TM, 
which is associated with endocrinopathies: 
hypogonadism, hypothyroidism, 
hypoparathyroidism, diabetes, liver fibrosis and 
heart dysfunction. Therefore, complicated and 
major focus in therapeutic management is iron 
overload.6-8 In addition, one of the causes of iron 
overload in TM patients is ineffective 
erythropoiesis,9,10 which leads to deficiency of 
vitamins and minerals.11,12 
Thalassemia appears to be common in coastal 
regions and lands with low altitudes.13,14 However, 
Haldane in 1949 suggested that, the high frequency 
of thalassemia gene in the places surrounding the 
Mediterranean Sea might be a consequence of 
positive selection by endemic malaria.15,16 Although 
some studies demonstrated that in addition to 
malaria, other factors play a selective role in 
geographic disturbance of thalassemia.17 Moreover, 
the reports from one study has shown that 
protective role of β-thalassemia against G6PD 
deficiency is attributed to the oxidative plants 
grown in low land areas, which provoke fauvism in 
patients with TM. 18 The results from some studies 
have shown that β-thalassemia patients seemed to 
be highly sensitive to hypoxia at high altitudes.16,18 
Hepcidin is an iron-regulatory hormone produced 
by hepatocytes which opposes iron absorption and 
erythropoiesis.19,20 Conditions such as iron overload, 
inflammation, anemia and hypoxia seem to 
decrease the production of this hormone which 
inhibits the effect of iron absorption and release of 
iron from macrophages, leading to increase in 
erythropoiesis.21 Another study has reported that 
Hepcidin might be reduced in healthy volunteers 
exposed to high altitude in both chronic and acute 
conditions.22 Moreover; it has been shown that low 
levels of Hepcidin in TM patients might be due to 
ineffective erythropoiesis activity23,24 which may be 
aggravate in high altitude. 
The aim of this study was to compare the effects of 
hypoxia on clinical features of TM patients at high 
and low altitudes, with respect to heart and liver 
functions. 
 
SUBJECTS AND METHODS 
   This is a multicenter, cross-sectional study 
conducted in Bushehr and Shahrekord cities in Iran 
on two groups of patients with β-thalassemia 
major. The first group was consisted of 50 patients 
and the second group was 40. They were matched 
by their sex and BMI. The first group was living in 
Bushehr Port in northern coast of Persian Gulf, at 
the sea level with barometric pressure of 1 
atmosphere and oxygen pressure of 160 mmHg. 
Bushehr is one the most prevalent cities of Iran for 
β-thalassemia and is appropriate for this research. 
The second group was living in Shahrekord located 
at the highest altitude (2061 m from sea level) in 
central area of Iran, with barometric pressure of 
600 mmHg, and oxygen pressure of 125 mmHg. 
 
Patients 
The patients were diagnosed by the clinical history, 
requirement for regular blood transfusion and 
laboratory tests including Complete Blood Count 
and Hemoglobin Electrophoresis. All selected 
patients were resident of the mentioned cities for 
at least 5 last years. The exclusion criteria were 
patients younger than 14 years old and those who 
had bone marrow transplant. 
The study was approved by ethics committee of 
Bushehr University of medical sciences and written 
informed consent was obtained from all patients. 
 
Assessment of the clinical features 
A stadiometer was used to measure height and 
weight. Body mass index was calculated. A 
questionnaire consisted of the characteristics and 
clinical features of the patients were completed by 
the help of an expert in the field. Information like 
transfusion requirement, splenectomy and diabetes 
history, puberty symptoms like menstruation or 
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ejaculation, bone fracture history and sleeping 
quality were checked from patients file in 
thalassemia ward or asked verbally and recorded. 
The average blood ferritin level of the TM patients 
measured during the previous one year (measured 
every two months by ELISA method) was obtained 
from thalassemia ward records. The patient’s 
cardiac function and hepatic status were evaluated 
by using echocardiography and magnetic resonance 
imaging respectively. General health questionnaire-
28 was also used for assessing patient’s General 
psychological health. 
 
Statistical analysis 
Probability values <0.05 were considered 
statistically significant. The significance of the 
difference in the results between the two groups 
was determined with chi-square analysis using 2*2 
contingency tables. A two-tailed t-test was used to 
compare the values across groups in the presence 
of a normal distribution. Spearman correlation 
analysis was employed to study the relationships 
among serum ferritin levels and patients age. All 
statistical analysis was performed using the PASW 
Gradpack 21 (SPSS Inc. Chicago, IL). 
 
RESULTS 
   The study consisted of 50 patients from Bushehr 
(26 male, 24 female) and 40 patients from 
Shahrekord (22 male, 18 female). The sex and age 
were matched and there was no difference in the 
two groups (p=0.777). The mean ferritin level in 
patients of Bushehr and Shahrekord was 1395.90 
ng/mL and 1206.59 ng/mL, respectively (Table 1). 
There was no significant difference in ferritin levels 
of two groups (p=0.296). There was no correlation 
between age and ferritin level (β=0.16, p=0.129). 
The mean transfusion period for patients in the first 
and second group was 20.74 and 23.08 days, 
respectively. There was no difference in their 
transfusion period between the two groups 
(p=0.072). It was found that cardiac function was 
significantly better in patients living in low altitude 
place (p=0.001). Also, after correction for age and 
comparing patients in age groups, a significant 
difference was noticed in cardiac function of the 
patients under the age of 20 (p=0.034) (Figure 1). 
We found that hepatic status was significantly 
better in patients of the first group (p=0.000) and 
after correction for age, there was a significant 
difference in liver function of the patients under the 
age of 24 years living in low altitude  city (p=0.008) 
(Figure 2). There was no difference between 
incidence of diabetes in both groups (p=0.129). 
However, 11 patients from Bushehr city and 4 
patients of Shahrekord suffered from diabetes. The 
result of this study showed that 20 patients from 
group 1 and 22 from group 2 were splenectomized. 
However, no significant difference was observed 
between the two groups (p=0.156). After correction 
for age and comparing patients in age groups, it was 
found that the patients under the age of 20 from 
the first group were less splenectomized (1 out of 
20), than the patients of the same age in the second 
group (8 out of 14). During the study 2 patients 
living in high altitude died. 
 
DISCUSSION 
   The purpose of this study was to compare the 
clinical features of TM patients in two different 
altitudes and find out whether low altitude has any 
positive effect on the disease process. Regarding 
the fact that Bushehr and Shahrekord are both 
located in Iran and the protocols that physicians use 
for their therapy and observation are the same. The 
results of this study showed no significant 
difference in serum ferritin level between the two 
groups. 
 
Table 1: Demographic and Clinical information of patients with β-
thalassemia major 
 Bushehr 
(n=50) 
Shahrekord 
(n=40) 
P value 
Sex M=26 
F=24 
M=22 
F=18 
0.777 
Mean Age (yrs) 23.8 
(14-41) 
21.33 
(14-29) 
0.156 
Mean Ferritin (ng/ml) 1395.9 1206.59 0.296 
Intervals of Transfusion 
(days) 
20.74 23.08 0.072 
Number 0f Diabetes 11 4 0.129 
Total cases of 
splenectomy 
20 22 0.156 
Splenectomy cases under 
age 20yrs 
1 of 20 8 of 14 *0.007 
F: (female), M: (male), yrs (years), ng/ml: (nanogram per mililitre), *: 
significant 
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Figure 1: Cardiac function in Thalassemia major patients of Bushehr and Shahrekord based on the echocardiography results 
 
 
 
Figure 2: Liver condition in Thalassemia major patients of Bushehr and Shahrekord based on MRI of liver 
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There were also no higher ferritin levels in older 
patients although they had transfusional therapy for 
a longer time. Since serum ferritin has been used to 
estimate iron overload,9 it was expected that the 
patients living in low altitude to have lower ferritin 
levels. The cause is, iron overload in these patients 
is not only depended to ineffective erythropoiesis 
and iron absorption but is mostly influenced by 
their transfusion diet and chelating therapy. 
Transfusion interval times in TM patients living in 
Bushehr were less than those in Shahrekord 
however, the difference was not significant. In this 
study, the transfusion diets were based on patient’s 
job and request. Other factors such as BMI or 
hemoglobin level were given low priority or 
ignored. Previous studies have shown that cardiac 
complications may be the cause of 50-70 percent of 
death in TM patients.25 Cardiac output 
measurement has been recommended for the 
assessment of cardiac function.26 Therefore, left 
ventricular ejection fraction (EF) above % 60 
considered to be normal.27 The results of the 
present study showed that, many of the patients 
living in low altitude had EF of above 60%. After 
adjusting age, better cardiac condition was also 
seen in younger patients living in low altitude. 
However, no difference was noticed in older 
patients. It may probably be due to long time 
transfusion and chronic cardiac iron overload. 
Diabetes and insulin resistance are common issue in 
TM patients (6-10%).28 We observed 16.6% 
prevalence of diabetes in our study but low altitude 
of living place had no relation with incidence of 
diabetes. 
MRI examination of the liver used to assess hepatic 
fibrosis and has been regarded as the golden 
standard for the total body iron overload.26 In the 
present study patients living in lower altitude had 
better hepatic status and after adjustment for age, 
this was also true in younger patients. According to 
previous studies liver iron overload worsens cardiac 
disease in TM patients and this can be an 
explanation for the difference in cardiac condition 
of the two groups.29 Splenomegaly and 
hypersplenism have been shown to be common in 
TM; they occur due to the excessive storage of 
iron.30,31 In addition, splenectomy is a way to reduce 
excessive blood consumption.32 In this study, no 
difference was found in the occurrence of 
splenectomy in the two groups. However, after 
adjusting for age, it was shown that younger 
patients living in high altitude experienced higher 
occurrence of splenectomy as compared to those in 
low altitude. The cause might be due to lack of 
sufficient therapeutic drugs and blood transfusion 
in the past decades; so, the spleen used to be 
removed in older TM patients routinely. However, 
in the present time splenectomy may be required 
only under conditions like increased transfusion 
requirement and hypersplenism.32 In addition to 
following results none of the patients living in 
higher altitude had the age of more than 29 as 2 of 
them passed away during 18 month of our research 
period but there were plenty of patients more than 
30 and 40 living in low altitude. 
The patients with TM living in high altitude probably 
experience lower levels of hepcidin in their blood 
circulation, leading to ineffective erythropoiesis 
which causes iron overload and life threatening 
dysfunctions. Although the low hepcidin level has 
been reported to rise after transfusion, it starts to 
fall again later.24 Since there was no transfusion or 
chelating therapy in the past centuries, TM patients 
probably developed ineffective erythropoiesis in 
very higher levels especially in higher lands and 
those patients would not have survived. So altitude 
might have played a selective role in geographic 
disturbance of thalassemia its self. 
One of the limitations of this study was the small 
size of the population under study. So, more studies 
with greater population and more specific in clinical 
features seems to be required to define the role of 
altitude in disease process of TM. Also, direct 
measurement of hepcidin before and after 
transfusion is suggested. 
 
CONCLUSION 
   The results of present study showed that living in 
low altitude may improve cardiac and liver function 
of TM patients. However there were no changes in 
ferritin level between the two groups which was 
suggested to be due to routine transfusion and 
chelating therapy. 
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